semaglutide biosimilar approvals are not expected before 2031 , preserving Novo Nordisks GLP-1 market branded revenue through the near-term forecast period
For weight loss specifically, tirzepatide is marketed under the brand name Zepbound
the elevated levels of ghrelin (187) and adiponectin (183)
Minimize bloating, abdominal discomfort, irritability, , and lower back pain
One case study showed improvement in functionality and pain scores for a person with EDS using collagen supplementation and proprioceptive rehabilitation, however the interventions were simultaneously administered making it hard to determine which intervention had the greatest impact (41)
Therefore, the outcome in our study has High reliability